✦ LIBER ✦

Lactation inhibition by the dopamine agonist CV 205–502

✍ Scribed by P.F.M. VAN DER HEIJDEN; J.A.M. KREMER; J. BROWNELL; R. ROLLAND

Book ID: 111155165
Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 477 KB
Volume: 98
Category: Article
ISSN: 1470-0328
DOI: 10.1111/j.1471-0528.1991.tb13392.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute overdose of a new dopamine agonist

Acute overdose of a new dopamine agonist, CV 205-502

✍ Igor Tauveron; Jean-Michel Gesta; Isabelle Jalenques; Philippe Thiebiot 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

Stimulation of dopamine D1 receptors by

Stimulation of dopamine D1 receptors by the D2 agonist CV 205–502 in bovine retina homogenates

✍ Saskia de Raad; Michel Schorderet 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 315 KB

CV205–502, A NEW NON-ERGOT DOPAMINE AGON

CV205–502, A NEW NON-ERGOT DOPAMINE AGONIST, REDUCES PROLACTINOMA SIZE IN MAN

✍ P. S. BARNETT; J. M. DAWSON; J. BUTLER; P. B. COSKERAN; J. J. MACCABE; A. M. McG 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 692 KB

Hormonal effects of CV 205–502, a novel

Hormonal effects of CV 205–502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties

✍ R.C. Gaillard; J. Brownell 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 471 KB

Antiparkinsonian activity of a non-ergot

Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease

✍ Dr. W. Poewe; G. Luef; B. Kleedorfer; M. Emre 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205‐502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L‐DOPA. CV 205‐502,

Disappearance of a pituitary tumor after

Disappearance of a pituitary tumor after 15 months of treatment with CV 205–502, a new dopamine agonist

✍ Faβbender, W. J. ;Stracke, H. ;Bachmann, G. ;Rau, W. ;Federlin, K. 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 482 KB

We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Immediately after diagnosis of a 12 x 10 mm intrasellar prolactinoma, treatment with CV 205-502 was begun at a daily dose o